Axios @axios
Medicare has initiated the process to determine whether it will deny, limit or allow full coverage of Aduhelm, the new Alzheimer's drug approved by the FDA despite no proof it effectively treats the brain disease. https://t.co/fh7XJYicrt — PolitiTweet.org